Unexplained longitudinal variability in COVID-19 antibody status by Lateral Flow Immuno-Antibody testing

Katrina Davis, Carolin Oetzmann, Ewan Carr, Grace Lavelle, Daniel Leightley, Michael Malim, Valentina Vitiello, Alice Wickersham, KCL-CHECK team, Reza Razavi[†], Matthew Hotopf[†]

Background

COVID-19 antibody testing allows population studies to classify participants by previous SARS-CoV-2 infection status. Home lateral flow immune-antibody testing devices offer a very convenient way of doing this, but relatively little is known about how measurement and antibody variability will affect consistency in results over time. We examined consistency by looking at the outcome of two tests three months apart while COVID-19 infection rates were low (summer 2020 in the UK).

Methods

The KCL-Coronavirus Health and Experiences in Colleagues at King's is an occupational cohort of staff and postgraduate research students. Lateral flow immune-antibody testing kits were sent to participant's homes in late June 2020 and late September 2020. Participants also completed regular surveys that included asking about COVID-19 symptoms and whether they thought they had been infected.

Results

We studied 1489 participants returned valid results in both June and September (59% of those sent kits). Lateral flow immune-antibody test was positive for 7.2% in June and 5.9% in September, with 3.9% positive in both. Being more symptomatic or suspecting infection increased the probability of ever being positive. Of those positive in June, 46% (49/107) were negative in September (seroreversion), and this was similar regardless of symptom characteristics, suspicion, and timing of possible infection. A possible outlier was those aged over 55 years, where only 3 of 13 (23%) had seroreversion.

Discussion

These results do not follow the pattern reported from studies specifically designed to monitor seropositivity, which have found greater consistency over time and the influence of presence, timing and severity of symptoms on seroreversion. We suggest several factors that may have contributed to this difference: our low bar in defining initial seropositivity (single test); a non-quantitative test known to have relatively low sensitivity; participants carrying out testing. We would encourage other studies to use these real-world performance characteristics alongside those from laboratory studies to plan and analyse any antibody testing.

Keywords: SARS-CoV-2, Cohort Studies, Seroprevalence, Lateral Flow Immunoantibody Testing

Background

Antibody testing in the community has been used to indicate prior infection with SARS-CoV-2, the virus that causes COVID-19. This is important for monitoring and understanding the long-term consequences of SARS-CoV-2 infection. Seropositivity to SARS-CoV-2 may also identify individuals more likely to be immunologically protected in future waves of COVID-19. Lateral flow immuno-antibody (LFIA) testing for immunoglobulin M and G (IgM/IgG) at point-of-care or sent to people's homes offers speed and convenience, with tests against gold-standard enzyme-linked immunoassay (ELISA) showing good accuracy of LFIA under lab conditions. (Pickering, Betancor et al. 2020) We previously reported the antibody status in June 2020 of participants in KCL-Coronavirus Health and Experiences in Colleagues at King's – KCL-CHECK, a cohort of staff and postgraduate research students (PGRs) at a large UK university - using SureScreen LFIA cassettes detecting IgG/IgM antibodies to the SARS-CoV-2 spike protein (Ig-S). (Leightley, Vitiello et al. 2020, Davis, Carr et al. 2021) . Comparison to other COVID-19 antibody studies suggested that the home use of LFIA in our cohort may have missed cases that would have been positive by more sensitive tests. Lower sensitivity may be an acceptable trade-off to avoid false positives and maximise usability.

One aspect of LFIA performance that remains unclear is consistency over time. To investigate this, we report on follow-up testing in the same cohort in September 2020 to look for inconsistencies that might be attributable to measurement and antibody variability. This will help to guide future users of home LFIA testing.

Methods

Elsewhere described (Davis, Stevelink et al. 2020, Davis, Carr et al. 2021) KCL-CHECK is a cohort of staff and postgraduate research students at a large university in London, United Kingdom. SureScreen LFIA devices and equipment needed to perform the test were sent to participants' home addresses in June 2020 and September 2020 (see Table 1). After completing the test, participants uploaded photographs of the results for interpretation by the research team, with any line in the control plus IgG and/or IgM being interpreted as positive (see supporting information Appendix S1 for the protocol and pictures of positive, negative and invalid test cassettes at Step 7). The only difference in the protocol between the two time-points was in how the buffer was supplied (see Appendix S1). Our previous paper compared the cohort with antibody results to the known characteristics of staff and PGRs, showing that women and people with White ethnicity were overrepresented.(Davis, Carr et al. 2021)

We collected general information about participants at baseline (April 2020). Core symptoms, symptom algorithm status and suspicion of COVID-19 were collected by survey. All participants in the antibody trial agreed to follow-up surveys every two months, with the majority also agreeing to surveys every two weeks. Any one of the following symptoms was considered a "core" symptom: a new persistent cough; fever; loss of smell or taste. More severely affected participants were identified by a symptom algorithm that also takes into accountsevere fatigue, loss of appetite, age and sex, (Menni, Valdes et al. 2020). Participants who thought they had "probably" or "definitely" experienced COVID-19 themselves were taken to indicate COVID-19 suspicion.

We present the survey results in three time periods: T0 February-April (pre-baseline), T1 May-June, and T2 June-September. The LFIA were sent out at the date indicated, but we accepted uploaded results for approximately a month after this, and some participants were mailed replacement kits at a later date. We have, however, used the first date possible, as this will ensure that, for example, exposure in T1 was very likely to have occurred before testing for antibodies in T1. Where participants have reported COVID-19 symptoms in multiple time-periods, we have taken the earlier

participants have reported COVID-19 symptoms in multiple time-periods, we have taken the earlier

report, to avoid persistent symptoms of COVID-19 being counted as a new infection. Participants were not excluded based on their completion of follow-up surveys. COVID-19 symptoms and suspicion were considered as 'ever reported' or 'not reported' at TO and across all completed surveys in T1, and again in T2, with no completion in a survey being treated as 'not reported'.

Table 1 Timina	of components o	FKCL-CHECK including	two testing windows
Tuble I Hilling	n combonents o	NCL=CHECK Cluu a	LWO LESLING WINDOWS

Date*	Time Period	Survey type for COVID-19 symptoms and suspicion	LFIA mailout
16/04/2020	T0	baseline ("since the start of the pandemic")	
04/05/2020	T1	fortnightly ("in the last two weeks")	
18/05/2020	T1	fortnightly ("in the last two weeks")	
01/05/2020	T1	fortnightly ("in the last two weeks")	
15/06/2020	T1	2 monthly ("in the last two months")	22 – 30 Jun
29/06/2020	T2	fortnightly ("in the last two weeks")	
13/07/2020	T2	fortnightly ("in the last two weeks")	
27/07/2020	T2	fortnightly ("in the last two weeks")	
10/08/2020	T2	2 monthly ("in the last two months")	
24/08/2020	T2	fortnightly ("in the last two weeks")	
07/09/2020	T2	fortnightly ("in the last two weeks")	15 – 23 Sep

^{*} Date survey opened. Email alert sent to the majority on day one, and a smaller subset on day eight. Survey closed on day 13.

Results

Most (2544, 91%) of the 2807 baseline cohort were eligible and elected to be sent an LFIA test. 1882 returned valid results for T1 and 1674 for T2, with 1489 (59% of sent, 53% of baseline) having valid results in both rounds of testing (see supporting information Figure S1), becoming our sample for analysis. The participant characteristics show that, compared to our baseline cohort, this sample under-represents PGRs and people with ethnicities other than White (see supporting information Table S1). The COVID-19 questions in each fortnightly survey were answered by between 92% to 82% of the sample (mean 88%). 58% (860/1489) of the sample answered at all ten surveys, 75% answered at least nine, and 92% answered at least five.

Table 2 shows that 107 of 1489 (7.2%) were positive at T1 and 83 (5.6%) were positive at T2, with only 58 (3.9%) positive at both. The number and timing of COVID-19 symptoms (core +/- algorithm) or suspicion are shown in supporting information Table S2. 715 participants (48%) reported symptoms and/or suspicion of COVID-19 at any time. Participants were much more likely to report COVID-19 symptoms or suspicion at T0 compared to T1 and T2, and most of those reporting suspicion or symptoms at T1 or T2 had already reported them at T0.

Table 2 Valid results from first two antibody testing windows in KCL-CHECK

		June 2020 (T1) LFIA result			
		Positive	Negative	total	
September (T2) LFIA result	Positive	58	25	83	
	Negative	49	1357	1406	
	total	107	1382	1489	

Table 3 and supporting information Figure S2 show the sequence of LFIA test results at T1 (positive/negative) and T2 (positive/negative) according to symptom algorithm, core symptoms and suspicion. The highest proportion of positive-positive occurred among those who were above cut-off on the symptom algorithm at T0 (17%). Inconsistent test results (either positive-negative or negative-positive) were common, at 56% of ever positive (74/132), and possibly more so for those presenting with COVID-19 symptoms or suspicion for the first time during T1 or T2. But only two of the 25 participants that converted from negative to positive had symptoms after T0, so COVID-19 infection shortly before the first test (T1) or between the first and second (T2) seems unlikely to account for this late seroconversion. There appears to be an increase in the proportion ever testing positive with increasing number of types of positive covid indicators. Of those who had not reported any symptoms or suspicion, 2.5% were ever seropositive, while of those with all three indicators (core symptoms, severe enough to score on the symptom algorithm and they suspected COVID-19 infection), 40% were ever seropositive.

Table 3 Sequence of LFIA IgG/IgM results by COVID-19 indicators and timings (also graphed in Figure S2)

Subgroup	First reported	number in subgroup	Proportion with sequence in group (T1-T2)				
			Positive-	Positive-	Negative-	Negative-	
			Positive	Negative	Positive	Negative	
Overall	Any	1489	3.9%	3.3%	1.7%	91.1%	
	<u>, </u>						
Symptom algorithm	Ever	256	14.1%	14.1%	3.5%	68.4%	
	TO	206	17.0%	15.5%	3.9%	63.6%	
	T1	30	3.3%	10.0%	3.3%	83.3%	
	T2	20	0.0%	5.0%	0.0%	95.0%	
Core Symptoms*	Ever	652	7.4%	6.6%	2.1%	83.9%	
	T0	541	8.5%	7.4%	2.2%	81.9%	
	T1	59	1.7%	5.1%	3.4%	89.8%	
	T2	52	1.9%	0.0%	0.0%	98.1%	
Suspected COVID-19	Ever	409	11.7%	10.0%	3.4%	74.8%	
Suspected COVID-19	TO	357	12.9%	10.0%	3.4%	73.1%	
	T1	40	0.0%	7.5%	0.0%	92.5%	
	T2	12	16.7%	16.7%	0.0%	66.7%	
None of the above	Ever	774	0.8%	0.4%	1.3%	97.5%	
Exactly 1 indicator	Ever	298	1.7%	1.3%	0.7%	96.3%	
Exactly 2 indicators	Ever	232	6.0%	4.3%	1.7%	87.9%	
All 3 indicators	Ever	185	17.8%	17.3%	4.9%	60.0%	

^{*} all participants with symptom algorithm are also in core symptoms

Of 107 with positive antibody results in T1, seropositivity was retained in T2 by 55% (58/107), which has a 95% confidence interval of 45-63%. Table 4 and supporting information Figure S3 show that the retention of antibodies for most subgroups was within the confidence interval of the sample. Outliers are the group aged 55+ years (above average at 77%). Those with a positive antibody result

in T1 whose first symptoms or suspicion were reported closer to the first testing (in T1) do not seem more likely to retain seropositivity (in fact the opposite), but there are small numbers in those groups. Supporting information Figure S4 and Figure S5 illustrate that more COVID-19 indicators also do not seem to lead to greater retention of seropositivity, as asymptomatic (no symptoms or suspicion at T0 or T1) have a similar retention proportion (64%) to those with one indicator (63%) and to having multiple indicators (52%).

Table 4 Retention of seropositivity, as a proportion of participants testing positive at T1 who remained positive at T2 (from those with valid test results at both times, n=1489)

		Number in group	Number positive antibody T1		Of which, number remain positive T2 (% of T1 @ T2)	
Total		1489	107	7%	58/107 54%	
Demographics	Gender	Female	1055	74	7%	40/74 54%
		Male	424	31	7%	17/31 55%
		Other / NA	10	2	20%	1/2 50%
	Age group	16-34y	606	54	9%	29/54 54%
	(years at	35-54y	658	40	6%	19/40 48%
	baseline)	55+y	225	13	6%	10/13 77%
COVID-19 symptoms	Symptom algorithm	Т0	206	67	33%	35/67 52%
		T1	30	4	13%	1/4 25%
	Core symptoms ⁺	ТО	541	86	16%	46/86 53%
		T1	59	4	7%	1/4 25%
	No core symptoms TO/		837	16	2%	10/16 63%
Suspect COVID-19	Suspected covid-19	ТО	357	82	23%	46/82 56%
		T1	40	3	8%	0/3 0%
	Not suspected TO/		1080	18	2%	10/18 56%

T0: first reported at baseline survey

Discussion

We report two rounds of antibody testing in an occupational cohort using LFIA at home after the first wave of COVID-19 in the UK. There was a variability in antibody test results obtained three months apart (timepoints T1 and T2) that was unexpected and not readily explained by the reported personal experience of COVID-19. 107 of 1489 (7.2%) participants tested positive at T1, with 58 (55%) remaining positive and 49 (45%) becoming negative at T2. Twenty-five participants who were negative at round one became newly positive in round two, accounting for 30% of those positive at T2, and not accounted for by COVID-19 symptoms or suspicion between testing time-points. Severity of symptoms of COVID-19 was related to the likelihood of ever testing positive, but not of retaining seropositivity. Recency of infection and gender did not affect proportion remaining positive, but there was a suggestion of older age groups being more likely to remain seropositive at T2.

T1: first reported in surveys after baseline and during T1

 $^{^{\}scriptscriptstyle +}$ All symptom algorithm positive participants are also in Core symptoms

The timing of symptoms and suspicion of COVID-19 in our sample accords with the known features of the early stages of epidemic in the UK, (Ward, Cooke et al. 2020) with most suspected infections in our population occurring before the end of April 2020. Our first LFIA testing directed towards antispike antibodies (primarily IgG-S) was in June. IgG-S levels are known to rise to a maximum level at around a month after infection. (Gudbjartsson, Norddahl et al. 2020, Korte, Buljan et al. 2020) Most studies have found levels declining after this, (Ibarrondo, Fulcher et al. 2020, Wu, Liu et al. 2020, Glück, Grobecker et al. 2021, Ward, Cooke et al. 2021) although others describe more of a plateau. (Gudbjartsson, Norddahl et al. 2020, Ortega, Ribes et al. 2021) In studies following IgG-S positive people for up to six months, some found little decline in seropositivity (García-Abellán, Padilla et al. 2021, Griffin, Tully et al. 2021), while some showed a substantial decline (Muecksch, Wise et al. 2020, Self 2020, Glück, Grobecker et al. 2021, Perez-Saez, Zaballa et al. 2021). In this analysis, among seropositive participants in June, 45% were negative in September. This exceeds levels of reversion seen in other studies, but it should be noted that these were usually restricted to people who had also tested positive for antigen or had repeated positive antibody tests. Compared to those with symptoms/suspicion in the first wave (TO, up to mid-April 2020), those few in our study who first reported symptoms/suspicion in T1 (April-June 2020) and tested positive in June were no more likely to remain seropositive in September, which is the opposite of what would be expected if recency of infection was playing a large part in the variability.

Use of the SureScreen LFIA and ELISA in hospitalised patients showed that IgG-S titres were more reliably detected in people with more severe COVID-19 illness. (Korte, Buljan et al. 2020, Wu, Liu et al. 2020) Other studies have shown that people who are symptomatic for COVID-19 remain seropositive more consistently than those who had an asymptomatic infection. (Ward, Cooke et al. 2020) We had three levels of COVID-19 symptoms among our sample: no core symptoms reported, core symptoms and algorithm positive. There was no evidence of increases in retention of seropositivity in more symptomatic cases, as retention was 63% with no core symptoms 52% with core symptoms and 52% in those with a positive algorithm. IgG-S titres have also previously been found to be higher in men than women and in older age groups, (Korte, Buljan et al. 2020, Wu, Liu et al. 2020) although they may subsequently fall faster. (Ward, Cooke et al. 2021) In our study, older participants were more likely to maintain seropositivity, which could be the outcome of having higher antibody titres after exposure but could be an artefact due to low numbers.

There is known to be substantial heterogeneity of COVID-19 antibody test results depending on the type of antibody probed and the kit used. (Kontou, Braliou et al. 2020, Favresse, Eucher et al. 2021, Jones, Mulchandani et al. 2021). For some LFIAs, heterogeneity has additionally been shown between batches of testing kits, lab versus point of care use, and the use of venous versus capillary blood. (Flower, Brown et al. 2020, Silveira, Mesenburg et al. 2021) Although the LFIA result have a very predictable relationship to antibody titres under tightly controlled conditions, (Ward, Cooke et al. 2021) in practice minor variations in the use of the LFIA, especially for people with modest levels of immunoglobulin, may give results that are above and below cut-off at the same actual immunoglobulin titre. (Favresse, Eucher et al. 2021, Silveira, Mesenburg et al. 2021) This may have contributed to our unexpected findings.

The strengths of this study are the use of a longitudinal cohort, allowing comparison of sequential testing, and COVID-19 indicators dating to the first wave of the pandemic, with good completion of frequent follow-up questionnaires. The same antibody test, batch of tests and near-identical protocol was used for both testing episodes, reducing variability from these causes. The mailing of kits allowed for greater participation at a time of heightened health concerns, but may have increased variability of use for a test kit that was designed for use by a healthcare professional.

ncreased variability of use for a test kit that was designed for use by a healthcare professional.

Despite the size of the cohort, we found numbers testing positive were low, which has affected the statistical power we could achieve. We were not able to look at antibody results in people severely affected by COVID-19 (i.e. requiring hospitalisation) as there were very low numbers. We did not perform antigen testing at the time of symptoms nor laboratory tests of antibodies. Participants were able to report tests done externally, but that data has not been shown here as access to testing was inconsistent and may bias results.

Conclusion

There is variability in people identified as seropositive through LFIA home testing over time that is not easily explained by symptom severity or timing. Therefore, we suggest that home antibody testing should be considered in the context of self-reported measures in research and the full presentation in clinical settings.

References

Davis, K. A., S. A. Stevelink, A. Al-Chalabi, G. Bergin-Cartwright, R. Bhundia, H. Burdett, E. Carr, G. Lavelle, D. Leightley and C. Middleton (2020). "The King's College London Coronavirus Health and Experiences of Colleagues at King's Study (KCL CHECK) protocol paper: a platform for study of the effects of coronavirus pandemic on staff and postgraduate students." medRxiv: doi: https://doi.org/10.1101/2020.1106.1116.20132456.

Davis, K. A. S., E. Carr, D. Leightley, V. Vitiello, G. Bergin-Cartwright, G. Lavelle, A. Wickersham, M. H. Malim, C. Oetzmann, C. Polling, S. A. M. Stevelink, R. Razavi and M. Hotopf (2021). "Indicators of past COVID-19 infection status: Findings from a large occupational cohort of staff and postgraduate research students from a UK university." medRxiv: 2020.2012.2007.20245183.

Favresse, J., C. Eucher, M. Elsen, C. Gillot, S. Van Eeckhoudt, J.-M. Dogné and J. Douxfils (2021). "Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection." <u>Microorganisms</u> **9**(3): 556.

Flower, B., J. C. Brown, B. Simmons, M. Moshe, R. Frise, R. Penn, R. Kugathasan, C. Petersen, A. Daunt and D. Ashby (2020). "Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey." Thorax **75**: 1082-1088.

García-Abellán, J., S. Padilla, M. Fernández-González, J. A. García, V. Agulló, M. Andreo, S. Ruiz, A. Galiana, F. Gutiérrez and M. Masiá (2021). "Long-term clinical, virological and immunological outcomes in patients hospitalized for COVID-19: antibody response predicts long COVID." medRxiv:2021.2003.2008.21253124.

Glück, V., S. Grobecker, L. Tydykov, B. Salzberger, T. Glück, T. Weidlich, M. Bertok, C. Gottwald, J. J. Wenzel, A. Gessner, B. Schmidt and D. Peterhoff (2021). "SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19." <u>Infection</u>.

Griffin, J., E. Tully, F. Cody, K. Edwards, K. Moran, D. LeBlanc, J. O'Loughlin, R. McLoughlin, R. Cummins, S. Breen, R. Drew, D. Natin and F. Malone (2021). "Persistence of SARS-CoV-2 antibodies and symptoms in an Irish Healthcare Worker (HCW) setting: Results of the COVID Antibody Staff Testing (CAST) Study." medRxiv: 2021.2002.2010.20248323.

Gudbjartsson, D. F., G. L. Norddahl, P. Melsted, K. Gunnarsdottir, H. Holm, E. Eythorsson, A. O. Arnthorsson, D. Helgason, K. Bjarnadottir and R. F. Ingvarsson (2020). "Humoral immune response to SARS-CoV-2 in Iceland." New England Journal of Medicine **383**: 1724-1734.

Ibarrondo, F. J., J. A. Fulcher, D. Goodman-Meza, J. Elliott, C. Hofmann, M. A. Hausner, K. G. Ferbas, N. H. Tobin, G. M. Aldrovandi and O. O. Yang (2020). "Rapid decay of anti–SARS-CoV-2 antibodies in persons with mild Covid-19." <u>New England Journal of Medicine</u>.

Jones, H. E., R. Mulchandani, S. Taylor-Phillips, A. E. Ades, J. Shute, K. R. Perry, N. L. Chandra, T. Brooks, A. Charlett, M. Hickman, I. Oliver, S. Kaptoge, J. Danesh, E. Di Angelantonio and D. Wyllie

```
(2021). "Accuracy of four lateral flow immunoassays for anti SARS-CoV-2 antibodies: a head-to-head comparative study." <u>medRxiv</u>: 2021.2001.2030.21250777.
```

Kontou, P. I., G. G. Braliou, N. L. Dimou, G. Nikolopoulos and P. G. Bagos (2020). "Antibody tests in detecting SARS-CoV-2 infection: a meta-analysis." <u>Diagnostics</u> **10**(5): 319.

Korte, W., M. Buljan, M. Rösslein, P. Wick, V. Golubov, J. Jentsch, M. Reut, K. Peier, B. Nohynek and A. Fischer (2020). "SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on." <u>Journal of Infection</u> **82**: e11-e14.

Leightley, D., V. Vitiello, G. Bergin-Cartwright, A. Wickersham, K. A. Davis, S. Stevelink, M. Hotopf, R. Razavi and K. C. r. team (2020). "The King's College London Coronavirus Health and Experiences of Colleagues at King's Study: SARS-CoV-2 antibody response in an occupational sample." medRxiv: doi: https://doi.org/10.1101/2021.1101.1126.21249744.

Menni, C., A. M. Valdes, M. B. Freidin, C. H. Sudre, L. H. Nguyen, D. A. Drew, S. Ganesh, T. Varsavsky, M. J. Cardoso, J. S. El-Sayed Moustafa, A. Visconti, P. Hysi, R. C. E. Bowyer, M. Mangino, M. Falchi, J. Wolf, S. Ourselin, A. T. Chan, C. J. Steves and T. D. Spector (2020). "Real-time tracking of self-reported symptoms to predict potential COVID-19." Nature Medicine 26(7): 1037-1040. Muecksch, F., H. Wise, B. Batchelor, M. Squires, E. Semple, C. Richardson, J. McGuire, S. Cleary, E. Furrie, N. Greig, G. Hay, K. Templeton, J. C. C. Lorenzi, T. Hatziioannou, S. J. Jenks and P. Bieniasz (2020). "Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents." medRxiv: 2020.2008.2005.20169128.

Ortega, N., M. Ribes, M. Vidal, R. Rubio, R. Aguilar, S. Williams, D. Barrios, S. Alonso, P. Hernández-Luis, R. A. Mitchell, C. Jairoce, A. Cruz, A. Jimenez, R. Santano, S. Méndez, M. Lamoglia, N. Rosell, A. Llupià, L. Puyol, J. Chi, N. R. Melero, D. Parras, P. Serra, A. Mayor, S. Barroso, P. Varela, A. Vilella, A. Trilla, P. Santamaria, C. Carolis, M. Tortajada, L. Izquierdo, A. Angulo, P. Engel, A. L. García-Basteiro, G. Moncunill and C. Dobaño (2021). "Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19." <u>medRxiv</u>: 2021.2002.2022.21252150.

Perez-Saez, J., M.-E. Zaballa, S. Yerly, D. O. Andrey, B. Meyer, I. Eckerle, J.-F. Balavoine, F. Chappuis, D. Pittet, D. Trono, O. Kherad, N. Vuilleumier, L. Kaiser, I. Guessous, S. Stringhini and A. S. Azman (2021). "Persistence and detection of anti-SARS-CoV-2 antibodies: immunoassay heterogeneity and implications for serosurveillance." medRxiv: 2021.2003.2016.21253710.

Pickering, S., G. Betancor, R. Pedro Galao, B. Merrick, A. W. Signell, H. D. Wilson, M. Tan Kia Ik, J. Seow, C. Graham, S. Acors, N. Kouphou, K. J. Steel, O. Hemmings, A. Patel, G. Nebbia, S. Douthwaite, L. O'Connell, J. Luptak, L. McCoy, P. J. Brouwer, M. J. van Gils, R. W. Sanders, R. Martinez Nunez, K. Bisnauthsing, G. O'Hara, E. MacMahon, R. Batra, M. H. Malim, S. J. Neil, K. Doores and J. D. Edgeworth (2020). "Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings." PLoS Pathogens: doi: https://doi.org/10.1371/journal.ppat.1008817.

Self, W. H. (2020). "Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network—12 States, April–August 2020." MMWR. Morbidity and mortality weekly report 69.

Silveira, M. F., M. Mesenburg, O. A. Dellagostin, N. R. Oliveira, M. A. C. Maia, F. D. S. Santos, A. M. Vale, A. Barros, L. P. Vidaletti and F. C. Barros (2021). "Time-Dependent Decay of Detectable Antibodies Against SARS-CoV-2: A Comparison of ELISA with Two Batches of a Lateral-Flow Test." Ward, H., G. Cooke, C. J. Atchison, M. Whitaker, J. Elliott, M. Moshe, J. C. Brown, B. Flower, A. Daunt and K. E. Ainslie (2020). "Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults." medRxiv.

Ward, H., G. S. Cooke, C. Atchison, M. Whitaker, J. Elliott, M. Moshe, J. C. Brown, B. Flower, A. Daunt, K. Ainslie, D. Ashby, C. A. Donnelly, S. Riley, A. Darzi, W. Barclay and P. Elliott (2021). "Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults." <u>The Lancet Regional Health - Europe</u> 4: 100098.

Wu, F., M. Liu, A. Wang, L. Lu, Q. Wang, C. Gu, J. Chen, Y. Wu, S. Xia and Y. Ling (2020). "Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China." <u>JAMA internal medicine</u> **180**(10): 1356-1362.